Zimmer Biomet Holdings controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile2 entries
2022
Criticism over continued Russian business
A Yale-linked assessment of corporate responses to Russia's invasion of Ukraine classified Zimmer Biomet as continuing business as usual in Russia, prompting criticism of its market position and lack of withdrawal.
2017
DOJ and SEC regulatory resolution
Zimmer Biomet announced a resolution with the U.S. Department of Justice and Securities and Exchange Commission involving approximately $30.5 million in penalties.